Introduction
Serendipitous discovery of antitumor activity of cisplatin [cisdiamminedichloridoplatinum(II)] (Fig. 1B) and ensuing introduction of cisplatin, carboplatin [cis-diamminecyclobutanedicarboxylatoplatinum(II)], nedaplatin [cis-diammineglycolatoplatinum(II)] and oxaliplatin {[(1R,2R-diamminocyclohexane)oxalatoplatinum(II)] (diaminocyclohexane = DACH)} into the clinical use evoked a renaissance in inorganic chemistry and led to the synthesis and biological evaluation of many thousands of cisplatin analogues, and a thorough investigation of other nearby elements from the periodic table (for example, gold, osmium, palladium and ruthenium) [1, 2] . Much of the early effort in the design of new platinum drugs was aimed at making cisplatin-based therapy safer to patients, in particular, lessening or removing unpredictable and severe nephrotoxicity and/or providing oral bioavailability. A second major, ongoing, initiative is to overcome tumor resistance to cisplatin, either that acquired during cycles of therapy with cisplatin (as occurs in patients with, for example, ovarian cancer [3, 4] ) or intrinsic resistance (such as that seen in patients with, for example, colorectal, prostate, lung or breast cancer [5] [6] [7] ).
Cisplatin and its analogues bind to various cellular components like DNA, RNA, proteins, and membrane phospholipids. The important target leading to cell death is genomic DNA [8] [9] [10] , although targets other than DNA may be also important for these agents [11] [12] [13] . Nevertheless, it is generally accepted that an important feature of mechanism of action of cisplatin and its analogues is their binding to nuclear DNA and subsequent blockage of transcription while eluding repair [14] [15] [16] [17] .
Cisplatin, carboplatin and nedaplatin form in DNA the same major 1,2-GG intrastrand cross-links (CLs) [15] , whereas DNA intrastrand and interstrand CLs of oxaliplatin are different [18, 19] and may account in part for its different spectrum of activity observed in combination with 5-fluorouracil/leucovorin. Success of oxaliplatin, which incorporates the 1R,2R-DACH carrier ligand as Pt II complex, raised considerable research interest over the past three decades in platinum-DACH complexes. Thus, in a search for more effective platinum antitumor complex that is also capable of overcoming cisplatin resistance in vivo a large-ring chelate complex [PtCl 2 (cis-1,4-DACH)] (Fig. 1A ) was synthesized and tested for cytotoxicity in tumor cell lines and for antitumor activity against the murine leukemias and human solid tumors [20] . Interestingly, this analogue features a mode of metal-ligand chelation in which the cis-1,4-DACH ligand is bonded to Pt II in a locked boat conformation. The cis-[PtCl 2 (1, ] complex has shown great clinical promise [20] [21] [22] . The findings that it exhibits better in vitro cytotoxicity than cisplatin [20] and also has substantial in vivo activity in L1210 leukemia cell lines resistant to oxaliplatin suggest that differences in shape or conformation of platinum complexes are important in eliciting the antitumor activity of [PtCl 2 (cis-1,4-DACH)] complex [21, 22] . These results have been interpreted to mean [23] that the [PtCl 2 (cis-1,4-DACH)] complex is neither a cisplatin-nor a [PtCl 2 (1R,2R-DACH)]-type analogue but rather a system that incorporates properties of both. Hence, the encouraging antitumor activity of [PtCl 2 (cis-1,4-DACH)] coupled with a considerably enhanced aqueous solubility compared to [PtCl 2 (1R,2R-DACH)] is an impetus for studies focused on the mechanistic basis of biological (pharmacological) effects of this complex.
The first mechanistic studies focused on unique antitumor effects of [PtCl 2 (cis-1,4-DACH)] were performed only recently [23, 24] . These studies have revealed that the [PtCl 2 (cis-1,4-DACH)] forms a seven-member chelating ring with platinum, which leads to considerable strain during bidentate [PtCl 2 (cis-1,4-DACH)] binding. Moreover, in [PtCl 2 (cis-1,4-DACH)], the N-Pt-N bite angle (978) is much larger than those found in other Pt II complexes with bidentate diamines or in cisplatin (918). Such a large angle could enhance the steric interactions between cis purine residues in bifunctional adducts of [PtCl 2 (cis-1,4-DACH)]. These recent results led to the hypothesis that [PtCl 2 (cis-1,4-DACH)] forms DNA adducts having the conformation different from that of DNA adducts of cisplatin or oxaliplatin. As DNA is considered the major pharmacological target of cisplatin and its analogues [14, 16] , the proposed difference in DNA binding mode of [PtCl 2 (cis-1,4-DACH)] has been suggested to be associated at least in part with more favorable biological (pharmacological) effects of 1,4-DACH analogue [23, 24] . A primary objective in the present work was to understand more fully the molecular mechanism of action of [PtCl 2 (cis-1,4-DACH)]. Four early steps in the mechanism of biological activity of cisplatin and its analogues have been delineated, namely: cell entry, reactions with sulfur-containing compounds, platinum-DNA binding and processing of platinated DNA by proteins (enzymes) and DNA repair. Here, we describe experiments revealing (i) cytotoxicity of [PtCl 2 (cis-1,4-DACH)] in human ovarian cell lines A2780 and A2780cisR (sensitive and resistant to cisplatin, respectively), i.e. in the tumor cell lines most frequently used to test cytotoxicity of cisplatin and its analogues, 
Materials and methods

Chemicals
[PtCl 2 (cis-1,4-DACH)] was prepared as described previously [24] . Purity of [PtCl 2 (cis-1,4-DACH)] was higher than 95% as established by combustion analysis carried out with a Hewlett Packard 185 C, H, and N analyzer. Cisplatin and trans-diamminedichloridoplatinum(II)] (transplatin) were obtained from Sigma (Prague, Czech Republic) (purity was !99.9% based on elemental and ICP trace analysis). The stock solutions of platinum compounds were prepared at the concentration of 5 Â 10 À4 M in 10 mM NaClO 4 and stored at 4 8C in the dark. Calf thymus (CT) DNA (42% G + C, mean molecular mass ca. 20 000 kDa) was prepared and characterized as described previously [25, 26] . Plasmids pSP73KB [2455 base pairs (bp)] and pSP73 (2464 bp) were isolated according to standard procedures. The synthetic oligodeoxyribonucleotides were synthesized and purified as described previously [27] . T4 DNA ligase, Klenow fragment from DNA polymerase I (exonuclease minus, mutated to remove the 3 0 ! 5 0 proofreading domain) (KF À ), restriction endonucleases EcoRI, HindIII, NdeI, SspI, Circum Vent TM Thermal Cycle Sequencing Kit with Vent(exo À ) DNA polymerase and T4 polynucleotide kinase were purchased from New England Biolabs (Beverly, MA). Deoxyribonucleoside 5 0 -triphosphates (dNTPs) were from Roche Diagnostics, GmbH (Mannheim, Germany). Agarose was from FMC BioProducts (Rockland, ME). Acrylamide, bis(acrylamide), ethidium bromide (EtBr), urea and NaCN were from Merck KgaA (Darmstadt, Germany). Dimethyl sulfate, KMnO 4 , diethyl pyrocarbonate (DEPC), glutathione (GSH), KBr and KHSO 5 were from Sigma (Prague, Czech Republic). Proteinase K, ATP and dNTPs were from Boehringer (Mannheim, Germany). Rabbit metallothionenin isoform designated MT-2 (Zn7-MT-2) was a kind gift of Prof. M. Vasak (University of Zurich, Zurich, Switzerland). Radioactive products were from Amersham (Arlington Heights, IL, USA). A cell-free extract (CFE) was prepared from the repair proficient HeLa S3 cell line as described [28, 29] . Taq polymerase and Q solution were from Qiagen (BIO-CONSULT spol. s.r.o., Prague, Czech Republic). SybrGreen 1 was from Molecular Probes (Leiden, The Netherlands).
Cytotoxicity
Cisplatin and [PtCl 2 (cis-1,4-DACH)] were dissolved in dimethylsulfoxide (DMSO). The stock solutions (100 mM) of the Pt compounds in DMSO were diluted with the aqueous cell culture medium in several steps immediately after their dissolution in DMSO. The final concentration of DMSO in cell culture medium did not exceed 0.25%. The A2780 (parent cisplatin sensitive) and 
Cellular platinum uptake
Cellular uptake of [PtCl 2 (cis-1,4-DACH)] and cisplatin was measured in A2780 cells (sensitive to cisplatin). The cells were seeded in 60 mm tissue culture dishes (30 000 per cm 2 ). After overnight incubation, the cells were treated with the platinum compound for 4 or 24 h at the concentrations of 2.7 mM. The cell monolayers at the end of the incubation with the Pt complex were washed (twice) with ice-cold phosphate buffered saline (PBS), trypsinized and harvested into cold (4 8C) PBS. Cell suspensions were centrifuged and the pellets were stored in PBS at À80 8C until assayed. Afterward, the pellets were digested with 12 M HCl and platinum content determined by flameless atomic absorption spectrophotometry (FAAS). The results of cellular platinum uptake were corrected for adsorption effects [30] . All experiments were made in quadruplicate.
Reactions with sulfur-containing compounds
Reactions of GSH and mammalian MT-2 with [PtCl 2 (cis-1,4-DACH)] and cisplatin were investigated by monitoring UV absorption at 260 nm of solutions containing the platinum complex and GSH or MT-2 exactly as described in the previous work [31, 32] ; the absorbance at 260 nm reflects the presence of platinum-sulfur and disulfide bonds. The platinum compounds (from aged stock solutions equilibrated in 10 mM NaClO 4 ) were mixed with GSH or MT-2 at 37 8C in the medium of 10 mM NaClO 4 plus 0.1 mM phosphate buffer, pH 7.0, in the dark. Reactions were initiated by mixing the platinum complex with the buffer followed by immediate addition of GSH or MT-2. The experiments were made in triplicate. The kinetic data were fitted by non-linear regression (GraphPad Prism) to one-phase and two-phase exponential association. The decision as to which fit was more appropriate for each dependence was made by comparing the fits of the two equations by using an F-test (GrahPad Prism).
Platination reactions in cell-free media
CT or plasmid DNAs were incubated with the platinum complex in 10 mM NaClO 4 at 37 8C in the dark. After 24 h, the samples were exhaustively dialyzed against the medium required for subsequent biochemical or biophysical analysis. An aliquot of these samples was used to determine the value of r b by FAAS, or by differential pulse polarography (DPP) [33] .
The duplexes containing single, central 1,2-GG intrastrand CL of cis-[Pt(1,4-DACH)] 2+ or cisplatin in the pyrimidine-rich top strands were prepared as described [27, 34] . The platinated oligonucleotides were purified by ion-exchange high-pressure liquid chromatography (HPLC). It was verified by platinum FAAS and by the measurements of the optical density that the modified oligonucleotides contained one platinum atom. It was also verified using dimethyl sulfate footprinting of platinum on DNA [34, 35] 0 end-labeled 20-mer SP6 primer recommended by the manufacturer with small modifications [37] . The synthesis products were separated by electrophoresis on a denaturing polyacrylamide (PAA) gel (6% PAA/ 8 M urea); sequence ladders were obtained in parallel using untreated control DNA fragment.
Interstrand cross-link assay
The [PtCl 2 (cis-1,4-DACH)] complex at varying concentrations were incubated for 24 h with 500 ng of pSP73KB DNA after it had been linearized by EcoRI and 3 0 -end labeled by means of KF À and [a-32 P]dATP. The amount of interstrand CLs was analyzed by electrophoresis under denaturing conditions on alkaline agarose gel (1%). After the electrophoresis was completed, the intensities of the bands corresponding to single strands of DNA and interstrand cross-linked duplex were quantified. The frequency of interstrand CLs, %ICL/Pt (the number of interstrand CLs per adduct), was calculated as %ICL/Pt = XL/4910Ár b (pSP73KB plasmid contained 4910 nucleotide residues) [35] . XL is the number of interstrand CLs per molecule of the linearized DNA duplex which was calculated assuming Poisson distribution of the interstrand CLs as XL = Àln A, where A is the fraction of molecules running as a band corresponding to the non-cross-linked DNA.
Unwinding of negatively supercoiled DNA
Unwinding of closed circular supercoiled pSP73KB plasmid DNA was assayed by an agarose gel mobility shift assay [38] . The unwinding angle F, induced per Pt-DNA adduct was calculated upon the determination of the r b value at which the complete transformation of the supercoiled to relaxed form of the plasmid was attained. Samples of pSP73KB plasmid were incubated with platinum compounds at 37 8C in the dark for 24 h. The samples were subsequently subjected to electrophoresis on 1% agarose gels running at 25 8C in the dark with TAE (Tris-acetate/EDTA) buffer. The gels were then stained with EtBr, followed by photography with transilluminator.
Chemical modifications
The modification by KMnO 4 , DEPC and KBr/KHSO 5 were performed as described previously [27, [39] [40] [41] . The strands of the 22-bp duplex TGGT(22) (its nucleotide sequence is shown in Fig. S2A ) were 5 0 -end-labeled with [g-32 P]ATP. In the case of the platinated oligonucleotides, the platinum complex was removed after reaction of the DNA with the probe by incubation with 0.2 M NaCN (pH 11) at 45 8C for 10 h in the dark. Other details of these experiments were as described in previous papers [42] [43] [44] .
Ligation and electrophoresis of oligonucleotides
Inhibition of DNA polymerization
The primer extension assays with all four dNTPs were performed with the 23-mer templates containing a single 1,2-GG intrastrand adduct of cis-[Pt(1,4-DACH)]
2+ or cisplatin which were prepared in the same way as described in Section 2. were withdrawn and the reactions in these aliquots were terminated by the addition of 5 mL of loading buffer containing 20 mM EDTA, 95% formamide, 0.3% bromphenol blue and 0.3% xylenecyanol blue and by heating at 90 8C for 1 min. The reaction products were resolved on 24% PAA gels containing 8 M urea and then visualized and quantified. Other details were published previously [45, 46] .
Steady-state kinetic analysis for dCTP incorporation opposite the 3 0 platinated G involved in the 1,2-GG intrastrand CL of cisplatin or [PtCl 2 (cis-1,4-DACH)] or this G contained in the unplatinated template catalyzed by KF À was done as described previously [47] [48] [49] [50] . Briefly, KF À was incubated with DNA substrates generated by annealing the 23-mer template containing site-specific adducts of [PtCl 2 (cis-1,4-DACH)] or cisplatin to the 16-mer 5 0 -32 P labeled oligomer primer ( Fig. S3 ) with increasing concentration of dCTP (in the absence of other deoxyribonucleotide triphosphates) for 5 min under standard reaction conditions (vide supra). Gel band intensities of the substrates and products were visualized and quantified. The percentage of primer extended (the sum of the integrated intensities of bands corresponding to all products 17 or more nucleotides long [47] [48] [49] [50] ) was plotted as a function of dCTP concentration, and the data were fitted by non-linear regression using GraphPad software to the Michaelis-Menten equation describing hyperbola, v ¼ ðV max Â ½dCTP=K m þ ½dCTPÞ. Apparent K m and V max steadystate parameters were obtained from the best fit and were used to calculate the efficiency of the dCTP insertion opposite the template 1st (3 0 ) platinated G to the efficiency of the dCTP insertion opposite this G which was unplatinated [(V max /K m ) platinated template / (V max /K m ) unplatinated template ].
DNA repair synthesis by human cell extract
DNA repair synthesis of CFEs of DNA repair proficient HeLa cells was assayed as described previously [51] [52] [53] extracted with 1 volume of 1:1 phenol:chloroform. The DNA was precipitated from the aqueous layer by the addition of 0.1 volume of 3 M sodium acetate and 2.5 volumes of ethanol. After 30 min of incubation at À20 8C and centrifugation at 12,000 Â g for 30 min at 4 8C, the pellet was washed with 0.2 mL 70% ethanol and dried. DNA was finally linearized by SspI (which cuts only once within pSP73 plasmid) before electrophoresis on a 1% agarose gel. The resulting gel was stained by SybrGreen 1 according to the manufacturer's protocol and the radioactivity associated with the bands was quantitated. The experiments were made in quadruplicate.
DNA repair in cells
Detection of gene-specific repair in cells was performed as described previously [54] [55] [56] . Briefly, A2780 cells were treated with [PtCl 2 (cis-1,4-DACH)] and cisplatin (200 mM) for 5 h, followed by treatment with 0.1 M thiourea for 1 h to block the conversion of monoadducts to CLs during the post-treatment incubation. The cells were then incubated for times up to 6 h in drug-free medium. Cells were harvested, total genomic DNA was isolated and the DNA concentration of the samples was determined by UV spectrophotometry. The DNA was then restriction-digested with HindIII at 37 8C for 2 h, and extracted using phenol/chloroform followed by ethanol precipitation. The pellet was resuspended in TE buffer (10 mM Tris, pH 8.0, 1 mM EDTA), the final DNA concentration recovered was determined as described above and quantitative PCR of an 1858-bp fragment of the DHFR gene was performed. Each PCR amplification mixture (25 ml) consisted of 150 ng of total genomic DNA and contained 0.625 U of Taq polymerase Qiagen, primers (0.5 mM for each primer; sense primer, 5 0 -ACGTAGCTCGTCCTCAAA, antisense primer, 5 0 -GCACTGGTAAACTTCATCAAG, dNTPs (0.2 mM each), 1Â Qiagen PCR buffer, 1Â Q solution (Qiagen), 2.6 mM MgCl 2 , and made up to 25 mL with Milli-Q water. The PCR conditions employed involved an initial denaturation at 96 8C for 5 min, 29 cycles of 96 8C for 1 min, 58 8C for 1 min, 72 8C for 1.5 min, and a final equilibration for 5 min at 72 8C. The amplification products were then resolved on a 1% agarose gel in 1Â Tris/acetate/EDTA buffer, pH 7.0. The gel was then stained with SyberGreen, then destained in water and the bands were quantitated. The Poisson distribution was used to calculate the number of adducts in the amplified fragment of the gene and the repair efficiency was expressed as the percentage of initial adducts that remained at that time point.
Other physical methods
Absorption spectra were measured with a Beckman 7400 DU spectrophotometer and quartz cells with a thermoelectrically controlled cell holder and quartz cells with a path length of 1 cm. Purification of oligonucleotides with the aid of HPLC was carried out on a Waters HPLC system consisting of Waters 262 pump, Waters 2487 UV detector, and Waters 600S controller with MonoQ HR 5/50 GL column. The FAAS measurements were carried out on a Varian AA240Z Zeeman atomic absorption spectrometer equipped with a GTA 120 graphite tube atomizer. For FAAS analyses, DNA was precipitated with ethanol and dissolved in HCl (0.1 M). DPP was performed with an EG&G Princeton Applied Research Corporation Model 384B Polarographic Analyzer. The gels were visualized by using a BAS 2500 FUJIFILM bioimaging analyzer, and the radioactivity associated with bands was quantitated with the AIDA image analyzer software (Raytest, Germany).
Results
Cytotoxicity
The cytotoxic activity of the [PtCl 2 (cis-1,4-DACH)] complex tested in the present work was determined against A2780 (parent cisplatin sensitive) and A2780cisR (with acquired cisplatin resistance) human ovarian carcinoma cell lines, commonly used to test cytotoxic activity of cisplatin analogues and other antitumor metallodrugs. A2780cisR cells are resistant to cisplatin through a combination of decreased uptake, enhanced DNA repair/tolerance, and elevated reduced glutathione levels [57] . The tumor cell lines were incubated for 72 h with the platinum compounds and the cell survival in the culture treated with the platinum compounds was evaluated as described in Section 2.2. Results (Table 1) show that [PtCl 2 (cis-1,4-DACH)] is significantly more cytotoxic than cisplatin. Interestingly, the cytotoxicity of [PtCl 2 (cis-1,4-DACH)] in the cisplatin-resistant line A2780cisR is characterized by lower value of resistance factor ( Table 1) .
Cellular uptake
The factor that is usually thought to contribute to platinum drug cytotoxicity is also cellular uptake. To examine accumulation of [PtCl 2 (cis-1,4-DACH)], the cellular levels of this compound were measured after a short (4 h) or long time (24 h) exposure of the A2780 cells to the drugs. Consistent with its enhanced cytotoxicity, the uptake of [PtCl 2 (cis-1,4-DACH)] was approximately 1.3-2-fold greater than that of cisplatin (Table 1) .
Reactions with sulfur-containing compounds
Pt
II compounds have a strong thermodynamic preference for binding to sulfur donor ligands. Hence, before antitumor platinum drugs reach DNA in the nucleus of tumor cells, they may interact with various compounds, including sulfur-containing molecules. These interactions are generally thought to play a role in mechanisms underlying tumor resistance to platinum compounds, their inactivation, and their side effects [58] . Therefore, interest in the interactions of platinum antitumor drugs with sulfur-containing molecules of biological significance has recently increased markedly. Examples of endogenous thiols to which platinum complexes bind when they are administered intravenously or after they enter the cell are GSH and metallothioneins (MTs). MTs are small ($6-7-kDa) cellular metalloproteins that strongly bind metal ions. The metal ion binding domains of MT isoform designated MT-2 consist of 20 cysteine residues arranged in two thiol (S)-rich sites [59] .
In the present work, we investigated reactions of GSH and mammalian MT-2 with [PtCl 2 (cis-1,4-DACH)] and cisplatin using UV absorption spectrophotometry [31, 32] . [PtCl 2 (cis-1,4-DACH)] or cisplatin with MT-2 (one-phase exponential association) were similar (212 AE 5 or 224 AE 6 min, respectively).
3.4. DNA modification in a cell-free medium 3.4.1. DNA binding One of the important early phases of the mechanism by which platinum compounds exert their anticancer activity is formation of adducts on nuclear DNA by these agents [16, 17, 60] . Hence, data on DNA binding mode of platinum complexes are of great interest. In the present study, we have applied some methodologies previously developed for cisplatin and its analogues to investigate the reaction products of [PtCl 2 (cis-1,4-DACH)] with DNA in cell-free media.
In order to determine the character of DNA adducts of [PtCl 2 (cis-1,4-DACH)] we examined the DNA binding properties of this complex and compared these binding properties with those of parent cisplatin. The first experiments were aimed at quantifying the binding of [PtCl 2 (cis-1,4-DACH)] to mammalian DNA. Solutions of double-helical CT DNA at a concentration of 0.056 mg/mL were incubated with [PtCl 2 (cis-1,4-DACH)] at the value of r i of 0.05 in 10 mM NaClO 4 at 37 8C (r i is defined as the molar ratio of free platinum complex to nucleotide phosphates at the onset of incubation with DNA). At various time intervals, an aliquot of the reaction mixture was withdrawn and assayed by DPP for platinum not bound to DNA. No changes in the pH of the reaction mixture containing DNA and platinum compounds were measured within 48 h after mixing DNA with the platinum complex. The amount of the platinum compound bound to DNA increased with time. In this binding reaction the time at which the binding reached 50% (t 50% ) was 65 AE 8 min (Table 1) . Thus, the [PtCl 2 (cis-1,4-DACH)] complex was quantitatively bound after 24 h. This result indicates that the rate of binding of [PtCl 2 (cis-1,4-DACH)] to natural double-helical DNA is higher than that of cisplatin or transdimminedichloridoplatinum(II) (transplatin) (t 50% = ca. 120 min [61] ).
The binding experiments of the present work indicate that the modification reactions resulted in the irreversible coordination of [PtCl 2 (cis-1,4-DACH)] to polymeric double-helical DNA, which also facilitates sample analysis. Hence, it is possible to prepare easily and precisely the samples of DNA modified by the platinum complex at a preselected value of r b . The samples of DNA modified by [PtCl 2 (cis-1,4-DACH)] or cisplatin and analyzed further by biophysical or biochemical methods were prepared in 10 mM NaClO 4 at 37 8C. If not stated otherwise, after 24 h reaction of DNA with the complex, the samples were precipitated in ethanol, dissolved in the medium necessary for a particular analysis and the r b value in an aliquot of this sample was checked by FAAS. In this way, the analyses described in the present paper were performed in the absence of unbound (free) platinum complex.
Replication mapping of platinum-DNA adducts
This procedure involved the extension by VentR(exo À ) DNA polymerase at the 3 0 -end of the primer up to the metal adduct on the template strand of pSP73 DNA. The products of the synthesis were then examined on DNA sequencing gels, and the sequence specificity of the platinum adduct formation was determined to the exact base pair. In vitro DNA synthesis on DNA templates containing the adducts of [PtCl 2 (cis-1,4-DACH)] generated a population of DNA fragments, indicating that the adducts of this complex effectively terminate DNA synthesis (Fig. 2A, lane 1,4 -DACH). Sequence analysis of the termination sites produced by [PtCl 2 (cis-1,4-DACH)] suggests a strong preference of DNA binding to dG sites and in some extent also to dA sites (Fig. 2B) , i.e. this platinum complex exhibited a sequence preference identical to that of cisplatin and different from that of ineffective transplatin (compare lanes 1,4-DACH with cisPt and transPt in Fig. 2A ).
Interstrand cross-linking
Bifunctional platinum compounds, which coordinate base residues in DNA, form various types of interstrand and intrastrand CLs. Considerable evidence suggests that the antitumor efficacy of bifunctional platinum compounds is the result of the formation of these lesions, but their relative efficacy remains unknown. Therefore, we have decided to quantitate the interstrand cross-linking efficiency of [PtCl 2 (cis-1,4-DACH)] in linearized pSP73KB plasmid. This plasmid DNA was linearized by EcoRI (EcoRI cuts only once within pSP73KB plasmid) and globally modified by [PtCl 2 (cis-1,4-DACH)], cisplatin or transplatin. The samples were analyzed for the interstrand CLs by agarose gel electrophoresis under denaturing conditions [35] . Upon electrophoresis, 3 0 -end labeled strands of linearized pSP73 plasmid containing no interstrand CLs migrate as a 2456-base single strand, whereas the interstrand cross-linked strands migrate more slowly as a higher molecular mass species (Fig. 3) . The experiments were carried out with DNA samples that were modified by the platinum complex at various r b values. The intensity of the more slowly migrating band increased with the growing level of the platination. The radioactivity associated with the individual bands in each lane was measured to obtain estimates of the fraction of non-cross-linked or cross-linked DNA under each condition. The DNA interstrand cross-linking efficiency of the [PtCl 2 (cis-1,4-DACH)] was 6 AE 1% (Table 1) . It implies that interstrand CLs represent only minor portion of the adducts formed in DNA by [PtCl 2 (cis1,4-DACH)].
Unwinding of negatively supercoiled DNA
Electrophoresis in native agarose gel was used to determine the unwinding induced in negatively supercoiled pSP73KB plasmid by monitoring the degree of supercoiling [38] (Fig. 4) . A compound that unwinds the DNA duplex reduces the number of supercoils in closed circular DNA so that their number decreases. This decrease upon binding of unwinding agents causes a decrease in the rate of migration through agarose gel, which makes it possible to observe and quantify the mean value of unwinding per one adduct. Fig. 4 shows electrophoresis gels from the experiment in which variable amounts of cisplatin or [PtCl 2 (cis-1,4-DACH)]
have been bound to a mixture of relaxed and negatively supercoiled pSP73KB DNA. The mean unwinding angle is given by F = À18s/r b (c), where s is the superhelical density and r b (c) is the value of r b at which the supercoiled and nicked forms comigrate [38] . Under the present experimental conditions, s was calculated to be À0.0505 on the basis of the data of cisplatin for which the r b (c) was determined in this study and F = 138 was assumed. Using this approach, the DNA unwinding angle of 15 AE 28 was determined.
Chemical probes of DNA conformation
The replication mapping experiments demonstrated that [PtCl 2 (cis-1,4-DACH)] binds to DNA at the same sites as cisplatin, which preferentially forms 1,2-intrastrand CLs between two neighboring guanine residues. In addition, [PtCl 2 (cis-1,4-DACH)] forms on DNA minor interstrand CLs at the same frequency as cisplatin. Thus, it is reasonable to assume that 1,2-GG intrastrand CLs are also the major lesions formed on DNA by [PtCl 2 (cis-1,4-DACH)]. Therefore, in the next experiments, we have focused on the characterization of the DNA perturbations induced in DNA by 1,2-GG intrastrand CL of [PtCl 2 (cis-1,4-DACH)].
To further characterize the conformational distortion induced in DNA by the 1,2-GG intrastrand CLs of [PtCl 2 (cis-1,4-DACH)], the 22-bp oligonucleotide duplex [TGGT (22) shown in Fig. S1A ] containing the single, site-specific 1,2-GG intrastrand CL of [PtCl 2 (cis-1,4-DACH)] (and for comparative purposes also the CL of cisplatin) was treated with several chemical agents that are used as tools for monitoring the existence of conformations other than canonical B-DNA. These agents include KMnO 4 , DEPC, and bromine. These probes react, under the conditions used, with base residues in single-stranded DNA and distorted doublestranded DNA, but not with the base residues in intact, doublestranded DNA [27, [39] [40] [41] . For this analysis, we used exactly the same methodology as in our recent studies dealing with DNA adducts of various antitumor platinum drugs. Thus, the details of this experiment can be found in those articles and representative gels showing piperidine-induced specific strand cleavage at KMnO 4 -modified, KBr/KHSO 5 -modified and DEPC-modified bases in the 22-bp duplex unplatinated or containing single, interstrand CL of [PtCl 2 (cis-1,4-DACH)] or cisplatin are demonstrated in Fig. S1A . The results are schematically summarized in Fig. S1B and Table 1 . The pattern and degree of reactivity toward the 
DNA unwinding and bending by 1,2-GG intrastrand cross-link of [PtCl 2 (cis-1,4-DACH)]
Among the alterations of secondary and tertiary structure of DNA, the role of intrinsic bending of DNA is increasingly recognized as of potential importance in regulating replication, transcription and repair functions through specific DNA-protein interactions. For DNA adducts of cisplatin, the structural details responsible for bending and subsequent protein recognition have recently been elucidated [62, 63] . Given the recent advances in our understanding of the structural basis for the bending of DNA caused by 1,2-GG intrastrand CL of cisplatin, it is of considerable interest to examine how the same adduct of [PtCl 2 (cis-1,4-DACH)] affects conformational properties of DNA such as unwinding and bending. In this work we further performed studies on the bending and unwinding induced by the single, site-specific 1,2-GG intrastrand CL of [PtCl 2 (cis-1,4-DACH)] formed in oligodeoxyribonucleotide duplexes.
As in the previous studies [19, 64] (Fig. S2B) . The results are summarized in Table 1 . The DNA bending toward the major groove of 33 AE 18 and unwinding 19 AE 28 due to the single, site-specific 1,2-GG intrastrand CL formed by [PtCl 2 (cis-1,4-DACH)] were found. The direction of the bend was determined using the 33-bp duplexes, which also contained, besides the single 1,2-GG intrastrand CL formed by [PtCl 2 (cis-1,4-DACH)], the (A-T) 5 tract located ''in phase'' from the CL (the cross-linked base pair and the center of the A tract were separated by 11 bp), in the same way as in our recent articles [65] [66] [67] . Also produced in ligations of monomers investigated in this work were separate bands arising from small DNA circles that migrate close to the top of the gel (see the bands marked by asterisk in Fig. S2B ). The highest tendency to yield DNA circles was observed for the 22-bp multimers confirming a close match between the 22-bp sequence repeats and the helix screw [68, 69] . Taken together, the major 1,2-GG intrastrand CL bends DNA in the same way as the same adduct of cisplatin whereas this CL formed by [PtCl 2 (cis-1,4-DACH)] in the sequence TGGT unwinds DNA somewhat more.
Inhibition of DNA polymerization
It has been demonstrated that DNA modifications by various platinum complexes have significant effects on processivity of a number of prokaryotic, eukaryotic, and viral DNA polymerases [45, [70] [71] [72] [73] [74] [75] . Interestingly, with DNA templates containing sitespecifically placed adducts of various platinum compounds, a number of prokaryotic and eukaryotic DNA polymerases were blocked but could also traverse through platinum adducts, depending on their character and conformational alterations induced in DNA. It is therefore of great interest to examine whether DNA polymerases, processing DNA substrates containing 1,2-GG intrastrand CL of [PtCl 2 (cis-1,4-DACH)] and cisplatin could reveal potential differences in alterations imposed on DNA by CLs of these two Pt II complexes which differ in the nonleaving amine ligands.
We investigated in the present work DNA polymerization using the templates site-specifically modified by the 1,2-GG intrastrand CL of [PtCl 2 (cis-1,4-DACH)] or cisplatin by KF À as a model and well characterized enzyme frequently used in the studies aimed at understanding the processes in which nucleic acid polymerases take part. We constructed, for the first series of experiments (''running start'' [48] ), the 12-mer/23-mer primer-template duplexes (Fig. 5A ) unplatinated or containing single 1,2-GG intrastrand CL of the cis-Pt II complex. The first 12 nucleotides on the 3 0 terminus of the 23-mer template strand were complementary to the nucleotides of the 12-mer primer so that the 3 0 guanine involved in the CL on the template strand was located at its 17th position from the 3 0 terminus (Fig. 5A) . After annealing the 12-nucleotide primer to the 3 0 terminus of the unplatinated or platinated template strand (positioning the 3 0 -end of the primer five bases before the adduct in the template strand), we examined DNA polymerization through the 1,2-GG intrastrand CL of [PtCl 2 (cis-1,4-DACH)] or cisplatin by KF À in the presence of all four dNTPs. The reaction was stopped at various time intervals, and the products were analyzed using a sequencing gel (Fig. 5A ). Polymerization by KF À using the 12-mer/23-mer primer-templates containing the 1,2-GG intrastrand CL of [PtCl 2 (cis-1,4-DACH)] or cisplatin in the presence of all four dNTPs proceeded rapidly up to the nucleotide opposite the base immediately downstream from the CL and the 3 0 guanine involved in the CL, such that the 16-and 17-nucleotide intermediate products accumulated to a significant extent (shown in Fig. 5A ). There was only a slight accumulation of longer DNA intermediates and more extensive accumulation of full length (23-nucleotide) products in particular using the templates containing the CL of cisplatin, whereas no full length products and only a very slight accumulation of longer intermediate products were seen with the template containing the CL of [PtCl 2 (cis-1,4-DACH)]. No intermediates, but only full length products were seen with the 23-mer unplatinated control template (shown in Fig. 5A ).
For the other series of experiments (''standing start'' [48] ), we constructed the 16-mer/23-mer primer-template duplexes (Fig. 5B ) unplatinated or containing 1,2-GG intrastrand CL of the cis-Pt II complex. The first 16 nucleotides on the 3 0 terminus of the 23-mer template strand were complementary to the nucleotides of the 16-mer primer (Fig. 5B) . Thus, after annealing the 16-nucleotide primer to the 3 0 terminus of the unplatinated or platinated template strand (positioning the 3 0 -end of the primer only one base before the adduct in the template strand), we examined DNA polymerization through the 1,2-GG intrastrand CL of [PtCl 2 (cis-1,4-DACH)] or cisplatin by KF À in the presence of all four dNTPs in the same way as in the case of the ''running start'' experiment (Fig. 5A) . Polymerization by KF À using the 16-mer/23-mer primer-template containing the 1,2-GG intrastrand CL of cisplatin in the presence of all four dNTPs proceeded rapidly only up to the 3 0 guanine involved in the CL (so that only one nucleotide was added), such that the 17-nucleotide intermediate products accumulated to some extent (shown in Fig. 5B) 0 -primer termini situated across the platinated G were determined as a function of dCTP concentration under steady-state conditions. For purposes of comparison, the kinetic parameters of dCTP insertion opposite this G residue contained in the unplatinated template were measured as well. From the kinetics of dCTP incorporation, the steady-state apparent K m and V max values for the incoming dCTP opposite the template platinated 3 0 G in the 1,2-GG-intrastrand CL of [PtCl 2 (cis-1,4-DACH)] or cisplatin or this G residue contained in the unplatinated template were obtained from the curves fitted to the Michaelis-Menten equation in the same way as in the previous papers (see e.g. Refs. [47] [48] [49] [50] ). The patterns of deoxyribonucleotide incorporation by KF À opposite the 1st (3 0 ) G residue contained in the 1,2-GG-intrastrand CL of [PtCl 2 (cis-1,4-DACH)] or cisplatin are shown in Fig. S3A and B, respectively. The K m and V max parameters were determined and used to calculate the percentage of dCTP incorporated opposite the platinated G residues ( Table 2) .
As indicated by the V max /K m values, KF À inserted dCTP opposite the 1st (3 0 ) G residue contained in the 1,2-GG-intrastrand CL of cisplatin about 200-fold less efficiently than opposite this G which was contained in the unplatinated template. In contrast, incorporation of dCTP by KF À opposite the 1st (3 0 ) G in the same CL of [PtCl 2 (cis-1,4-DACH)] was even more than 3000-fold less efficient than opposite this G which was contained in the unplatinated template. The substantially lower efficiency of dCTP incorporation opposite the 1st (3 0 ) G contained in the 1,2-GG-intrastrand CL of the Pt II complexes resulted from a 164 and 2935-fold increase in the K m ( Table 2) . The results of experiments demonstrating the effects of major DNA adducts of [PtCl 2 (cis-1,4-DACH)] and cisplatin on DNA polymerization indicate that the character of these adducts and alterations induced in DNA by these adducts were distinctly different so that the replacement of nonleaving ammine groups in cisplatin by a large-ring cis-1,4-DACH carrier ligand led to DNA adducts that could potentially impede elongation of DNA markedly more effectively. ] or cisplatin to induce damage, followed by treatment with thiourea (to prevent the slow conversion of monoadducts to CLs) before the cells were allowed to repair the damage. The DNA was then isolated and analyzed for the presence of platinum lesions in the DHFR gene. In A2780 cells, as seen in Fig. 7 , lesions induced by [PtCl 2 (cis-1,4-DACH)] were repaired rapidly, with 55 AE 5% of lesions removed within 6 h. Similar results were obtained for the repair of cisplatininduced lesions, 64 AE 5% of total lesions were repaired in 6 h. Hence, the results of this experiment confirmed that also in cells [PtCl 2 (cis-1,4-DACH)] adducts are removed from DNA with only slightly slower repair kinetics than DNA adducts of cisplatin, in agreement with the in vitro results obtained using CFEs.
Discussion
[PtCl 2 (cis-1,4-DACH)] proved to be quite toxic to the tumor cells, with IC 50 values that were lower than those observed for cisplatin [20] (Table 1) . Interestingly, the cytotoxicity of [PtCl 2 (cis-1,4-DACH)] in the cisplatin-resistant line A2780cisR is also characterized by a lower resistance factor ( Table 1) .
The origin of the improved pharmacological effects of [PtCl 2 (cis-1,4-DACH)] may be multifactorial. The major pharmacological factors affecting platinum drug cytotoxicity are cellular uptake and efflux; structure and frequency of target (DNA) adducts, including their intracellular processing; and metabolic deactivation by sulfur nucleophiles [16, 76] . All these factors combine to affect signaling pathways, leading to apoptosis or necrosis of tumor cells.
The present study reveals that the cellular uptake of [PtCl 2 (cis-1,4-DACH)] is considerably greater than that of cisplatin (Table 1) . (Table 1 ). In contrast, this 1,4-DACH compound is pronouncedly more potent also in the tumor cell line A2780cisR resistant to cisplatin (Table 1) , which is known to be resistant also through elevated levels of reduced GSH [79] . Hence, the unfavorable deactivation of Pt II compounds by GSH does not seem to be a strong determinant of cytotoxic effects of [PtCl 2 (cis-1,4-DACH)]. The adducts of conventional cisplatin and its analogues distort DNA conformation [15, 80] , inhibit replication and transcription (but they are also bypassed by DNA or RNA polymerases) [17, 81] , and trigger apoptosis or necrosis [82] . In addition, cisplatin adducts are removed from DNA mainly by nucleotide excision repair system [15, 80] and are also recognized by several proteins [83] . In broad terms, we have demonstrated that the DNA binding mode of [PtCl 2 (cis-1,4-DACH)], including sequence preference, type of the major adducts, and resulting conformational alterations, is not very different from that of cisplatin (Table 1 ). In contrast, there are differences in some factors associated with the DNA binding mode, which may be relevant to different biological effects of [PtCl 2 (cis-1,4-DACH)] and cisplatin. The major adducts of [PtCl 2 (cis-1,4-DACH)] are removed from DNA by DNA repair systems present in CFEs and in living cells as well with a slightly lower efficiency than the adducts of cisplatin (Fig. 6) . Hence, it cannot be excluded that they may persist somewhat longer on DNA than the adducts of cisplatin, which may potentiate probably only partially antitumor effects of [PtCl 2 (cis-1,4-DACH)].
Most interestingly, the 1,2-GG intrastrand CLs of [PtCl 2 (cis-1,4-DACH)] inhibit DNA polymerization more efficiently than the same adducts of cisplatin ( Fig. 5 and Fig. S3 , Tables 1 and 2) so that they can also be bypassed by DNA polymerases with greater difficulty. Numerous studies have indicated that the level of DNA adduct tolerance, which has been correlated with the increased ability of DNA polymerases to replicate DNA past platinum adducts, inversely correlates with sensitivity to platinum drugs [84, 85] . In other words, the sensitivity of tumor cells to platinum drugs can be enhanced as a consequence of a lowered adduct tolerance mediated by reduced ability of DNA polymerases to replicate past platinum adducts. We find in the present work that major DNA adducts of [PtCl 2 (cis-1,4-DACH)] impede elongation of DNA by a model prokaryotic DNA polymerase KF À to a markedly greater extent than those of cisplatin ( Fig. 5 and Fig. S3 , Tables 1 and 2) . Since there is a high degree of structural and sequence conservation of the domains among eukaryotic, prokaryotic, and viral polymerases [86] insights gleaned from studies of the KF À should be also applicable to other DNA polymerases [87] [88] [89] . Hence, the repercussion of stronger inhibition of DNA polymerization by the 1,2-intrastrand CL of [PtCl 2 (cis-1,4-DACH)] in comparison with the major adduct of cisplatin adds a new dimension to the impact of the replacement of the ammonia groups in cisplatin by cis-1,4-DACH ligand on biological processes, possibly including replication or DNA repair.
A gently tuned catalytically active structure of the ternary DNA polymeraseÁprimer/template DNAÁincoming dNTP complex is a prerequisite for correct course of the DNA polymerization reaction. In regard to the different effects of DNA adducts of [PtCl 2 (cis-1,4-DACH)] and cisplatin on the DNA polymerization reaction (Fig. 5 and Fig. S3 ), the formation of this ternary complex can be disturbed by (i) different conformational distortions imposed on the template DNA by the two Pt II complexes or (ii) steric clashes between the bulkier 1,4-DACH ligand of the DNA adduct and other components of the ternary complex, which do not occur in the case of considerably less bulky nonleaving ammonia ligands of the DNA adduct of cisplatin. As the conformational distortions induced in DNA by DNA adducts of [PtCl 2 (cis-1,4-DACH)] and cisplatin are similar (Table 1) , the bulk size appears to be a major factor responsible for the markedly lowered tolerance of DNA adducts of [PtCl 2 (cis-1,4-DACH)]. The inhibition of DNA polymerization by Pt-DNA adducts appears to be one of the most pronounced effects observed in the present work that could be responsible for markedly different effects of DNA adducts of [PtCl 2 (cis-1,4-DACH)] and cisplatin (Tables 1 and 2 ). The studies demonstrating lowered ability of DNA polymerases to replicate DNA past platinum adducts were performed in the present work using one of the most intensively studied DNA polymerases, a model prokaryotic DNA polymerase KF À of A-family of DNA polymerases, which has served as a prototype for studying DNA polymerase mechanisms [90] . Nevertheless, a more detailed study of DNA polymerization across and beyond the adducts of [PtCl 2 (cis-1,4-DACH)] and cisplatin using eukaryotic translesion DNA polymerases of Y-family are warranted. These studies are in progress in our laboratory in Brno and results of these detailed studies will be published in a separate report.
The cytotoxicity is the result of many events, beginning with the cell accumulation and proceeding through detoxification by thiols, DNA modification, and cellular responses to the DNA damage. It is not a simple task to reveal all aspects of the mechanism underlying antitumor effects of platinum complexes, and it is apparently incorrect to attribute cytotoxicity to their single property. Further studies are therefore warranted to reveal a relative contribution of all potential factors contributing to the potency of [PtCl 2 (cis-1,4-DACH)] in various types of cancer cells.
